Ingredient label guide

Yohimbine Supplement Guide: Claims, Label Red Flags & Safety

Yohimbine appears in fat burners, pre-workouts, and sexual-performance products, but the label may describe anything from a variable bark extract to a clearly dosed pharmacologically active compound.

Also listed as: yohimbine hydrochloride, yohimbine HCl, yohimbe bark, yohimbe bark extract, or Pausinystalia yohimbe. Related but different: alpha-yohimbine, also called rauwolscine.

NutriDetector Editorial Team Updated July 27, 2026 Editorial Policy

Overview

What are yohimbe and yohimbine?

Yohimbe is a tree native to central and western Africa. Its bark contains yohimbine and other alkaloids. Yohimbine is a pharmacologically active compound that blocks alpha-2 adrenergic receptors. ¹ ⁴ That mechanism helps explain its stimulant-style marketing, but a plausible mechanism is not evidence that a retail supplement produces a particular weight, performance, or sexual-health outcome.

The ingredient identity matters. Yohimbe bark is a botanical mixture; yohimbine HCl is a specific salt of isolated yohimbine; and alpha-yohimbine, also called rauwolscine, is a separate related compound. These names should not be merged or treated as interchangeable.

Why brands use these names

Yohimbe and yohimbine appear in products marketed for weight loss, athletic performance, energy, mood, libido, and erectile function. ¹ Those are marketing categories, not proof that the finished product is effective, accurately labeled, or suitable for a particular person.

Evidence and claims

What human evidence shows for yohimbine and yohimbe supplements

Standardized yohimbine used in older pharmacological trials is not equivalent to a yohimbe bark supplement with variable or undisclosed alkaloid content. Evidence must follow the actual ingredient identity and dose.

Yohimbe supplements

The National Center for Complementary and Integrative Health says there is very little human research on yohimbe as a dietary supplement and not enough evidence to reach definite conclusions about its effectiveness for any health condition. ¹

Weight loss and performance

Weight-loss findings are inconsistent. One 21-day trial in 20 professional soccer players reported lower estimated fat mass with 20 mg per day but no improvement in body weight, muscle mass, or athletic performance. Other controlled obesity trials have produced both positive and neutral results. These small, older studies do not establish yohimbine as a reliable or broadly safe weight-loss supplement. ¹ ⁹

Sexual function

Older trials studied standardized yohimbine, sometimes as a pharmacological treatment, rather than unpredictable yohimbe bark products. A later review reported a signal for erectile function across older trials, but yohimbine alone did not significantly improve the broader sexual-function outcome in that analysis. ⁶ These findings do not establish a retail yohimbe supplement as an effective treatment.

Read the label

The ingredient name determines what the milligrams mean

Illustrative label lines

These examples show how disclosure changes interpretation. They are not dosing recommendations.

Yohimbe bark extract – 100 mg: This states the mass of the extract, not the amount of active yohimbine. Without a declared yohimbine percentage or active amount, the yohimbine exposure cannot be calculated from the label.
100 mg, standardized to 2% yohimbine: The disclosure implies 2 mg of yohimbine per stated serving: 100 mg multiplied by 2%. This makes the label more interpretable, but it does not independently verify the bottle contents or establish a safe or effective dose.
Yohimbine HCl – 5 mg: This identifies 5 mg of the hydrochloride salt as declared on the label. It should not be interpreted automatically as 5 mg of yohimbine free base unless the label explicitly states an equivalent active-yohimbine amount.
10:1 yohimbe extract: An extraction ratio describes source-material concentration. It does not disclose the percentage or milligrams of yohimbine and should not be used to calculate active exposure.
Alpha-yohimbine / rauwolscine: Rauwolscine is a separate related alkaloid, not another spelling of yohimbine. Its identity and amount should remain separate in the formula. ⁵
Whole stimulant formula: Check the serving size, servings per day, proprietary blends, and co-listed stimulants such as caffeine. One disclosed ingredient does not describe the combined formula.

What a label cannot confirm

Clearer disclosure is not independent verification.

A study of 49 products purchased from major U.S. retailers found yohimbine amounts ranging from none detected to 12.1 mg per recommended serving. Only 11 labels stated a specific yohimbine amount; among those products, measured content ranged from 23% to 147% of the labeled amount. Only two of the 49 products combined an accurate quantity with information about known adverse effects. ²

This was a historical market sample, not an estimate of every product sold today. It does show why a label analysis can report the disclosed identity, amount, and standardization but cannot confirm the actual contents. It also cannot detect an ingredient omitted from the label. In June 2026, FDA reported finding undeclared yohimbine in a sexual-enhancement product after laboratory testing. ⁸

Rules also vary by market. In the European Union, yohimbe bark and preparations derived from it are prohibited for use in foods under Annex III, Part A of Regulation (EC) No 1925/2006. ⁷ That rule should not be generalized to every isolated medicinal product or every jurisdiction.

Safety and interactions

Safety cannot be reduced to one number on the label

Yohimbine has been associated with irregular heartbeat, blood-pressure problems, heart attack, and seizures. ¹ In a retrospective California Poison Control review of 238 symptomatic adult cases reported from 2000 through 2006, common effects included gastrointestinal distress, rapid heart rate, anxiety or agitation, and high blood pressure. The reports had higher odds of severe outcomes and health-care-facility management than poison-center exposures overall. ³ Poison-center cases are a safety signal, not an incidence estimate; they cannot show how often an effect occurs among all users.

Antidepressants: NCCIH says not to use yohimbe with monoamine oxidase inhibitors or tricyclic antidepressants.
Other stimulants and medicines: FDA warned in a 2026 adulterated-product notice that risks may be greater with caffeine, ephedra, ADHD stimulant medicines, MAO inhibitors, and certain antidepressants. ⁸
Pregnancy and breastfeeding: NCCIH says oral yohimbe might be unsafe during pregnancy or while breastfeeding.
Cardiovascular, seizure, or psychiatric history: reported blood-pressure, rhythm, seizure, anxiety, confusion, and other mental-health effects make label-only assessment inadequate.

These examples are not a complete interaction or contraindication list. A pharmacist or clinician should review the exact product and medication context; the absence of a warning on a supplement label is not medical clearance.

NutriDetector approach

How NutriDetector reads yohimbine labels

The analysis keeps yohimbe bark, yohimbine, yohimbine HCl, and alpha-yohimbine or rauwolscine as distinct identities. It checks disclosed extract mass, active amount or standardization, serving context, proprietary blends, and co-listed stimulants using maintained rules.

A result does not independently verify the bottle contents, detect undeclared yohimbine, test purity, establish legal status in every market, predict an individual response, clear medication interactions, or decide whether a person should take the product.

Analyze the full formula

Read the entire stimulant formula, not one name in isolation.

NutriDetector reviews disclosed identities, amounts, standardization, serving context, blends, and supported caution context. It cannot verify ingredients that are missing from the label.

Analyze a supplement label

Questions and boundaries

Yohimbine supplement FAQ

What is the difference between yohimbe and yohimbine HCl?

Yohimbe usually means bark or bark extract containing a variable mixture of alkaloids. Yohimbine HCl is a specific salt of isolated yohimbine. A stated HCl amount is easier to interpret than bark-extract milligrams alone, but that does not prove the product is safe, effective, accurately manufactured, or lawful in every market.

Is alpha-yohimbine the same as yohimbine?

No. Alpha-yohimbine, also called rauwolscine, is a related but separate alkaloid. It should have its own identity and amount on the label rather than being merged with yohimbine or generic yohimbe bark.

Is yohimbine proven for weight loss?

No reliable general conclusion can be made from the available evidence. Small, short studies of standardized yohimbine have reported isolated findings, but NCCIH says there is not enough research to conclude that yohimbe supplements are effective for obesity or athletic performance.

Can a yohimbe bark amount tell me the yohimbine dose?

Not by itself. Bark or extract milligrams describe the botanical material. To calculate the disclosed active amount, the label must also state a yohimbine percentage or a separate yohimbine amount. An extraction ratio such as 10:1 is not a yohimbine percentage.

Can yohimbine interact with medicines or other stimulants?

Yes. NCCIH specifically warns against combining yohimbe with monoamine oxidase inhibitors or tricyclic antidepressants, and FDA has identified higher risk with stimulant combinations and certain medicines. This is not a complete interaction list, so the exact product and medication context should be reviewed by a pharmacist or clinician.

Does a clearly stated yohimbine HCl amount mean the product is safe?

No. Clear disclosure makes the label easier to interpret. It does not independently verify the amount, establish purity or effectiveness, resolve interactions, account for the full stimulant stack, or determine personal suitability.

Scientific references and safety sources

National Center for Complementary and Integrative Health. Yohimbe: Usefulness and Safety. Updated May 2025. NCCIH.
Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Testing and Analysis. 2016;8(3–4):357–369. PubMed.
Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Annals of Pharmacotherapy. 2010;44(6):1022–1029. PubMed.
National Library of Medicine, PubChem. Yohimbine, CID 8969. PubChem.
National Library of Medicine, PubChem. Rauwolscine hydrochloride, CID 197067. PubChem.
Wibowo DNSA, Soebadi DM, Soebadi MA. Yohimbine as a treatment for erectile dysfunction: a systematic review and meta-analysis. Turkish Journal of Urology. 2021;47(6):482–488. PubMed.
European Commission. Commission Regulation (EU) 2019/650 as regards Yohimbe. EUR-Lex.
U.S. Food and Drug Administration. Business Pill may be harmful due to hidden drug ingredient. June 10, 2026. FDA.
Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Research in Sports Medicine. 2006;14(4):289–299. PubMed.